Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to destroy various cancers in Canada, the United States, and internationally. It operates in two divisions, Anti-Cancer Therapy and Medical Laser Technology. The company also designs, develops, manufactures, and commercializes medical laser systems and other technologies for the activation of PDCs; designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of healing, as well as TLC-1000 and TLC-2000 accessories; and Theralase therapeutic laser treatments for patients, including pain management, arthritis, wound healing, addiction rehabilitation and weight loss, and anti-aging, as well as companion animals and equine. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1995 and is headquartered in Toronto, Canada.
Industry, Sector and Symbol
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-416-6995273
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$972,333.00
Profitability
Miscellaneous
Employees20
Next Earnings Date3/6/2020 (Estimated)
OptionableOptionable
Theralase Technologies (CVE:TLT) Frequently Asked Questions
What is Theralase Technologies' stock symbol?
Theralase Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "TLT."
How were Theralase Technologies' earnings last quarter?
Theralase Technologies Inc. (CVE:TLT) posted its quarterly earnings data on Friday, November, 29th. The company reported ($0.01) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.01). The business earned $0.14 million during the quarter, compared to analysts' expectations of $0.30 million. View Theralase Technologies' Earnings History.
When is Theralase Technologies' next earnings date?
Has Theralase Technologies been receiving favorable news coverage?
News articles about TLT stock have been trending somewhat negative on Thursday, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Theralase Technologies earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Theralase Technologies.
Who are some of Theralase Technologies' key competitors?
What other stocks do shareholders of Theralase Technologies own?
Who are Theralase Technologies' key executives?
Theralase Technologies' management team includes the folowing people:
- Ms. Kristina Hachey, CFO & Director
- Dr. Arkady Mandel, Chief Scientific Officer & Director
- Mr. Roger John Dumoulin-White, Director of Bus. Devel.
- Dr. Shawn Shirazi Ph.D., Chief Exec. Officer
- Mr. David M. Groves B.A, Pres of World Trade Division
How do I buy shares of Theralase Technologies?
Shares of TLT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Theralase Technologies' stock price today?
One share of TLT stock can currently be purchased for approximately C$0.27.
How big of a company is Theralase Technologies?
What is Theralase Technologies' official website?
How can I contact Theralase Technologies?
Theralase Technologies' mailing address is 1945 Queen St E, TORONTO, ON M4L 1H7, Canada. The company can be reached via phone at +1-416-6995273.
MarketBeat Community Rating for Theralase Technologies (CVE TLT)
MarketBeat's community ratings are surveys of what our community members think about Theralase Technologies and other stocks. Vote "Outperform" if you believe TLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
